Physician profile
Harmon C Stein
NPI 1588624357
$6,597.19
in general payments reported to CMS, 2019-2025
34 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $564 · 2021: $1,021 · 2022: $1,191 · 2023: $810 · 2024: $1,496 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,809.39 | 2019-2025 | Hydrus Microstent, Wavelight Refractive Suite, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $548.78 | 2020-2022 | |
| Allergan, INC. | $444.69 | 2019-2022 | |
| New World Medical,INC. | $373.52 | 2021-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Galderma Laboratories, L.P. | $296.22 | 2021-2025 | Dysport |
| Horizon Therapeutics Plc | $233.50 | 2021-2023 | Tepezza |
| Abbvie INC. | $217.36 | 2022-2025 | Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $212.58 | 2022-2025 | Envista Mx60 Iol, Envista Envy Iol, Vyzulta |
| Mallinckrodt Hospital Products INC. | $152.79 | 2021 | |
| Glaukos Corporation | $141.93 | 2019-2022 | |
| Rxsight INC | $135.45 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.81 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $120.66 | 2019 | |
| Sight Sciences, INC. | $114.20 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Harrow Eye, LLC | $95.72 | 2024-2025 | Iheezo, Vevye |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $66.64 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $54.25 | 2020-2023 | Cequa |
| Merz North America, INC. | $49.88 | 2020 | |
| Amgen INC. | $45.89 | 2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $44.16 | 2023-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Ocular Therapeutix, INC. | $42.57 | 2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $37.95 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $31.79 | 2022 | |
| Revance Therapeutics, INC. | $27.78 | 2024 | Daxxify |
| Lkc Technologies, INC. | $24.52 | 2023-2024 | |
| Carl Zeiss Meditec USA, INC. | $22.33 | 2023 | Lumera 700 |
| Abb Con-Cise Optical Group LLC | $21.50 | 2022 | |
| Tearlab Corp | $19.87 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Spark Therapeutics, INC. | $18.78 | 2019 | |
| Travere Therapeutics, INC. | $16.26 | 2023 | Cholbam |
| Novartis Pharmaceuticals Corporation | $13.50 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.83 | 2021 | |
| Oasis Medical, INC. | $10.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmon Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.